Investing.com - Bristol-Myers Squibb (NYSE: BMY) reported fourth quarter EPS of $1.70, $0.10 better than the analyst estimate of $1.60. Revenue for the quarter came in at $11.48B versus the consensus estimate of $11.22B.
Guidance
Bristol-Myers Squibb sees FY 2024 EPS of $7.10-$7.40 versus the analyst consensus of $7.39.
Bristol-Myers Squibb's stock price closed at $48.67. It is down -7.80% in the last 3 months and down -34.63% in the last 12 months.
Bristol-Myers Squibb saw 0 positive EPS revisions and 14 negative EPS revisions in the last 90 days. See Bristol-Myers Squibb's stock price’s past reactions to earnings here.
According to InvestingPro, Bristol-Myers Squibb's Financial Health score is "great performance".
Check out Bristol-Myers Squibb's recent earnings performance, and Bristol-Myers Squibb's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar